基于MR的模型预测巨梁状-团块型肝细胞癌及其预后意义
研究纳入2007年6月至2021年3月间接受肿瘤切除的336例肝细胞癌患者,其中127例用于识别巨梁状-团块型肝细胞癌(MTM-HCC),209例用于预后分析,基于术前MRI影像组学与临床模型进行预测。影像组学模型在训练集和验证集识别MTM-HCC的AUC分别为0.916和0.833,临床模型分别为0.760和0.704;影像组学概率、门静脉或肝静脉癌栓、不规则环状动脉期高强化及AFP为无病生存期的独立预测因素,RAD-nM组无病生存期显著高于RAD-M组(P < .001)。
要点
- 基于术前MRI的影像组学模型识别MTM-HCC的验证集AUC为0.833(95%CI 0.675-0.935)。
- 临床模型识别MTM-HCC的验证集AUC为0.704(95%CI 0.532-0.843)。
- 影像组学概率、门静脉或肝静脉癌栓、不规则环状动脉期高强化及AFP为无病生存期独立预测因素。
核心结论
- 基于MR的临床和影像组学模型有潜力准确诊断MTM-HCC。
- 为识别MTM-HCC设计的影像组学特征也可用于预测肝细胞癌患者的预后,同时实现诊断和预后目的。
研究设计与样本
- 研究纳入2007年6月至2021年3月间接受肿瘤切除的肝细胞癌患者336例。
- Cohort1共127例患者用于MTM-HCC识别,Cohort2共209例患者用于预后分析。
- 影像组学分析基于术前MRI图像上勾画的肝细胞癌感兴趣体积。
- 影像组学和临床模型在Cohort1中使用随机森林算法开发,并从影像组学模型获得MTM-HCC的影像组学概率(RP)。
诊断标准与关键数值
- 影像组学模型识别MTM-HCC在训练集和验证集的AUC分别为0.916(95%CI 0.858-0.960)和0.833(95%CI 0.675-0.935)。
- 临床模型识别MTM-HCC在训练集和验证集的AUC分别为0.760(95%CI 0.669-0.836)和0.704(95%CI 0.532-0.843)。
- 基于RP将Cohort2患者分为RAD-MTM-HCC(RAD-M)组和RAD-non-MTM-HCC(RAD-nM)组。
- 影像组学生物标志物RP、门静脉或肝静脉癌栓、不规则环状动脉期高强化(IRE)及AFP为肝细胞癌患者无病生存期的独立预测因素。
临床应用与阅片要点
- 基于RP分组的RAD-nM组无病生存期显著高于RAD-M组(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the efficacy of MRI-based radiomics and clinical models in predicting MTM-HCC. Additionally, to investigate the ability of the radiomics model designed for MTM-HCC identification in predicting disease-free survival (DFS) in patients with HCC.
METHODS: A total of 336 patients who underwent oncological resection for HCC between June 2007 and March 2021 were included. 127 patients in Cohort1 were used for MTM-HCC identification, and 209 patients in Cohort2 for prognostic analyses. Radiomics analysis was performed using volumes of interest of HCC delineated on pre-operative MRI images. Radiomics and clinical models were developed using Random Forest algorithm in Cohort1 and a radiomics probability (RP) of MTM-HCC was obtained from the radiomics model. Based on the RP, patients in Cohort2 were divided into a RAD-MTM-HCC (RAD-M) group and a RAD-non-MTM-HCC (RAD-nM) group. Univariate and multivariate Cox regression analyses were employed to identify the independent predictors for DFS of patients in Cohort2. Kaplan-Meier curves were used to compare the DFS between different groups pf patients based on the predictors.
RESULTS: The radiomics model for identifying MTM-HCC showed AUCs of 0.916 (95% CI: 0.858-0.960) and 0.833 (95% CI: 0.675-0.935), and the clinical model showed AUCs of 0.760 (95% CI: 0.669-0.836) and 0.704 (95% CI: 0.532-0.843) in the respective training and validation sets. Furthermore, the radiomics biomarker RP, portal or hepatic vein tumor thrombus, irregular rim-like arterial phase hyperenhancement (IRE) and AFP were independent predictors of DFS in patients with HCC. The DFS of RAD-nM group was significantly higher than that of the RAD-M group (p < .001).
CONCLUSION: MR-based clinical and radiomic models have the potential to accurately diagnose MTM-HCC. Moreover, the radiomics signature designed to identify MTM-HCC also can be used to predict prognosis in patients with HCC, realizing the diagnostic and prognostic aims at the same time.
引用
- Chai F, Ma Y, Feng C, et al. Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications. Abdom Radiol (NY). 2023. PMID: 38042762. doi:10.1007/s00261-023-04121-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。